|本期目录/Table of Contents|

[1]罗光泽,潘红瑞,朱杰昌,等.紫杉醇药涂球囊治疗下肢动脉闭塞症的有效性及安全性分析[J].天津医科大学学报,2019,25(04):369-372.
　LUO Guang-ze,PAN Hong-rui,ZHU Jie-chang,et al.Efficacy and safety of drug-coated balloon angioplasty in the treatment of lower extremity arterial occlusive disease[J].Journal of Tianjin Medical University,2019,25(04):369-372.
点击复制

紫杉醇药涂球囊治疗下肢动脉闭塞症的有效性及安全性分析(PDF)
分享到：

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
25卷
期数:
2019年04期
页码:
369-372
栏目:
临床医学
出版日期:
2019-07-20

文章信息/Info

Title:
Efficacy and safety of drug-coated balloon angioplasty in the treatment of lower extremity arterial occlusive disease
文章编号:
1006-8147(2019)04-0369-04
作者:
罗光泽; 潘红瑞; 朱杰昌; 罗宇东; 范海伦; 冯 舟; 戴向晨
（天津医科大学总医院血管外科，天津300052）
Author(s):
LUO Guang-ze;  PAN Hong-rui;  ZHU Jie-chang;  LUO Yu-dong;  FAN Hai-lun;  FENG Zhou;  DAI Xiang-chen
(Department of Vascular Surgery, General Hospital,Tianjin Medical University, Tianjin 300052, China)
关键词:
下肢动脉硬化闭塞症; 药涂球囊; 紫杉醇; 补救性支架; 支架置入术
Keywords:
Lower extremity arterial occlusive disease; Drug-coated balloon angioplasty; Paclitaxel; Remedial stents; Stent imlantation
分类号:
R658.3
DOI:
-
文献标志码:
A
摘要:
目的：评价紫衫醇药涂球囊在下肢动脉硬化闭塞症腔内治疗中的有效性及安全性。方法：回顾性分析83例纳入股腘动脉闭塞病变临床试验的患者资料。结果：两组患者术前一般资料差异均无统计学意义（P ＞0.05）；药涂球囊组（DCB组）平均靶病变血管长度（8.4±5.3）cm显著长于非药涂球囊组（UCB组）（8.0±4.3）cm（P ＜0.05）；DCB组靶血管植入补救性金属裸支架率（23.6%）显著低于UCB组（42.6%）（P ＜0.01）。DCB组3、6及12个月一期通畅率均显著高于UCB组（P ＜0.01）。DCB组与UCB组患者均无随访期间死亡病例，UCB组目标肢体截肢率（7.1%）显著高于DCB组（0.0）（P ＜0.01）。结论：DCB在治疗下肢动脉硬化闭塞症病例临床疗效优于UCB，而且DCB治疗的安全性不劣于UCB。
Abstract:
Objective: To evaluate the efficacy and safety of the paclitaxel drug-coated balloon in the endovascular treatment of lower extremity arteriosclerosis obliterans. Methods: A retrospective analysis of 83 patients with clinical trials of femoral-popliteal artery occlusion disease was performed. Results：There was no statistically significant difference in preoperative data between the two groups (P >0.05). The average target lesion length (8.4±5.3)cm in the drug-coated balloon group(DCB group) was significantly longer than that in the uncoated balloon group (UCB group) (8.0±4.3)cm (P <0.05); the rate of target vessel implantation with remedial metal bare stent in DCB group (23.6%) was significantly lower than that in UCB group (42.6%) (P <0.01). The patency rates of the DCB group at 3, 6 and 12 months were significantly higher than those in the UCB group (P <0.01). No patients passed away during the follow-up period in the DCB group and the UCB group, and the target limb amputation rate in the UCB group(7.1%) was significantly higher than that in the DCB group (0.0%) (P <0.01). Conclusion： The clinical efficacy of DCB in the treatment of arteriosclerosis occlusions of lower limbs may be superior to UCB, and the safety of DCB treatment is not inferior to UCB.

参考文献/References:


[1] Spreen M I, Martens J M, Hansen B E, et al. Percutaneous transluminal angioplasty and Drug-Eluting stents for infrapopliteal lesions in critical limb ischemia（PADI）trial[J]. Circ Cardiovasc Interv,2016, 9(2): e002376
[2] Tsetis D, Uberoi R. Quality improvement guidelines for endovascular treatment of iliac artery occlusive disease[J]. Cardiovasc Intervent Radiol, 2008, 31(2):238
[3] 黄水传,黎思毅,张智,等. 腔内介入治疗下肢动脉硬化闭塞症的疗效观察[J]. 中国血管外科杂志:电子版, 2012, 4(3):169
[4] 郭伟,卫任. 药物涂层球囊治疗周围动脉疾病的循证医学证据[J].中国普通外科杂志, 2016, 25(6):785
[5] Clair D G, Beach J M. Strategies for managing aortoiliac occlusions: access, treatment and outcomes[J].Expert Rev Cardiovasc Ther,2015, 13(5):551
[6] Norgren L, Hiatt W R, Dormandy J A, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II)[J]. Eur J Vasc Endovasc Surg, 2007, 33(1):S5
[7] 张天华,迟德财,姜维良. 药物涂层球囊治疗下肢动脉硬化闭塞症的疗效[J]. 中国普通外科杂志,2016,25(12):1719
[8] Joner M, Byrne R A, Lapointe J M, et al. Comparative assessment of drug-eluting balloons in an advanced porcine model of coronary restenosis[J]. Thromb Haemost, 2011,105(5, SI):864
[9] Toelg R, Merkely B, Erglis A, et al. Coronary artery treatment with paclitaxel-coated balloon using a BTHC excipient: clinical results of the international real-world DELUX registry[J]. EuroIntervention,2014,10(5):591
[10] Siablis D, Kitrou P M, Spiliopoulos S, et al.Paclitaxel-Coated balloon angioplasty versus Drug-Eluting stenting for the treatment of infrapopliteal Long-Segment arterial occlusive disease the IDEAS randomized controlled trial[J]. JACC Cardiovasc Interv, 2014, 7(9):1048
[11] Rosenfield K,Metzger D C,Scheinert D. A Paclitaxel-Coated balloon for femoropopliteal artery disease REPLY[J]. N Engl J Med, 2015, 373(18):1785
[12] Mwipatayi B P, Hockings A, Hofmann M, et al. Balloon angioplasty compared with stenting for treatment of femoropopliteal occlusive disease: A meta-analysis[J]. J Vasc Surg, 2008, 47(2):461
[13] Kayssi A, Al-Atassi T, Oreopoulos G A, et al.Drug-eluting balloon angioplasty versus uncoated balloon angioplasty for peripheral arterial disease of the lower limbs[J]. Cochrane Database Syst Rev, 2016, 8(8):CD011319
[14] Tepe G, Laird J, Schneider P, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN. PACT SFA randomized trial[J].Circulation, 2015, 131(5):495
[15] Herdeg C, Oberhoff M, Baumbach A, et al. Local paclitaxel delivery for the prevention of restenosis: Biological effects and efficacy in vivo[J]. J Am Coll Cardiol, 2000, 35(7):1969
[16] 符伟国,岳嘉宁. 股腘动脉段病变支架内再狭窄的腔内治疗策略分析[J]. 中华外科杂志, 2016, 54(8):586
[17] Alfonso F, Cuesta J. Long-Term results of Drug-Coated balloons for Drug-Eluting In-Stent restenosis gaining perspective[J]. JACC Cardiovasc Interv, 2015, 8(7):885
[18] Ansari F, Pack L K, Brooks S S, et al. Design considerations for studies of the biomechanical environment of the femoropopliteal arteries[J]. J Vasc Surg, 2013, 58(3):804
[19] Scheinert D, Scheinert D, Duda S, et al. The Levant I (lutonix Paclitaxel-Coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization First-in-Human randomized trial of Low-Dose Drug-Coated balloon versus uncoated balloon angioplasty[J]. JACC Cardiovasc Interv, 2014,7(1):11
[20] Zeller T, Rastan A, Macharzina R, et al. Drug-Coated balloons vs. Drug-Eluting stents for treatment of long femoropopliteal lesions[J].J Endovasc Ther, 2014, 21(3):359

相似文献/References:

备注/Memo

备注/Memo:
基金项目 天津市科技支撑重点项目基金资助（16YFZCSY01080）
作者简介 罗光泽（1991-），男，硕士在读，研究方向：血管外科；通信作者：戴向晨，E-mail：13302165917@163.com。
更新日期/Last Update: 2019-08-28